title: Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor-independent pathway.
abstract: Infections caused by organisms of the Mycobacterium avium complex occur in approximately 50 to 60% of patients with AIDS. M. avium is an intracellular pathogen that survives and multiplies within mononuclear phagocytes. In this study, we investigated the uptake of M. avium grown within macrophages (intracellular growth M. avium [IG]) by a second macrophage compared with M. avium cultured in broth (extracellular growth M. avium [EG]). The results showed that IG was six- to eightfold more efficient than EG in entering macrophages. In addition, while an anti-CR3 antibody was able to inhibit approximately 60% of EG uptake by macrophages, it failed to inhibit the entry of IG. In contrast to EG, IG uptake into macrophages was significantly inhibited in the presence of anti-beta1-integrin and anti-transferrin receptor antibodies. Entry into macrophages by alternate receptors was associated with resistance to tumor necrosis factor alpha (TNF-alpha) stimulation. While stimulation with TNF-alpha resulted in inhibition of the growth of EG, it was not associated with inhibition of intracellular growth of IG. Investigation of the reason why M. avium is able to sense the changes in the intracellular environment triggering a change to the invasive phenotype suggests a direct relationship with macrophage apoptosis. These results suggest that intracellular growth is associated with novel mechanisms of M. avium uptake of macrophages and that those mechanisms appear to offer advantages to the bacteria in escaping the host defense.
authors.affiliation: Kuzell Institute of Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco 94115, USA.
authors.forename: L E
authors.initials: LE
authors.lastname: Bermudez
authors.forename: A
authors.initials: A
authors.lastname: Parker
authors.forename: J R
authors.initials: JR
authors.lastname: Goodman
mesh_terms: D019138:Antibodies, Blocking / Q000276:immunology; D017209:Apoptosis / Q000276:immunology; D002374:Catalase / Q000494:pharmacology; D003470:Culture Media; D053938:DNA Fragmentation; D016264:Dextran Sulfate / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D019012:Integrin beta1 / Q000276:immunology; D016177:Macrophage-1 Antigen / Q000276:immunology; D008264:Macrophages / Q000382:microbiology*; D008854:Microscopy, Electron; D015269:Mycobacterium avium Complex / Q000254:growth & development* / Q000276:immunology / Q000648:ultrastructure; D015270:Mycobacterium avium-intracellulare Infection / Q000276:immunology / Q000382:microbiology*; D010587:Phagocytosis / Q000276:immunology; D011134:Polysaccharides / Q000494:pharmacology; D011990:Receptors, Transferrin / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000494:pharmacology
chemical_list: D019138:Antibodies, Blocking; D003470:Culture Media; D019012:Integrin beta1; D016177:Macrophage-1 Antigen; D011134:Polysaccharides; D011990:Receptors, Transferrin; D014409:Tumor Necrosis Factor-alpha; D006493:Heparin; D016264:Dextran Sulfate; C007789:fucoidan; D002374:Catalase